Rachel Perret

Title: Rachel Perret: Innovator in Cancer Immunotherapy

Introduction

Rachel Perret is a prominent inventor based in Wellington, New Zealand. She has made significant contributions to the field of cancer immunotherapy, focusing on innovative approaches to target Ras neoantigens. Her work is vital in the ongoing battle against cancer, providing new avenues for treatment and prevention.

Latest Patents

Rachel Perret holds 2 patents related to her groundbreaking research. Her latest patents include compositions and methods for targeting Ras antigens to treat or prevent cancer. These patents disclose embodiments that include binding proteins, such as T cell receptors or chimeric antigen receptors, which bind to a Ras antigen:HLA complex. The polynucleotides encoding these binding proteins can be introduced into host cells, such as T cells, which can then be utilized in immunotherapy for treating various cancers. Additionally, her patents provide immunogenic polypeptides that can induce an immune response against mutated Ras or help identify binding proteins that target Ras antigens.

Career Highlights

Rachel Perret is affiliated with the Fred Hutchinson Cancer Center, where she continues her research and development in cancer therapies. Her work is characterized by a commitment to advancing medical science and improving patient outcomes through innovative solutions.

Collaborations

Rachel has collaborated with notable colleagues, including Philip D. Greenberg and Thomas M. Schmitt. These partnerships enhance her research efforts and contribute to the broader scientific community's understanding of cancer treatment.

Conclusion

Rachel Perret is a trailblazer in the field of cancer immunotherapy, with her innovative patents paving the way for new treatment options. Her dedication to research and collaboration underscores her impact on the fight against cancer.